Urinary Tract Infection and Neurogenic Bladder

Urologic Clinics of North America

Volumn 42, Issue 4, 2015, Pages 527-536

  McKibben, Maxim J ^a   Seed, Patrick ^b   Ross, Sherry S ^a   Borawski, Kristy M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibiotic prophylaxis; Antimicrobial resistance; Bacterial interference; Neurogenic bladder; Probiotics; Spina bifida; Spinal cord injury; Urinary tract infection

Indexed keywords

ANTIBIOTIC AGENT; ASCORBIC ACID; BOTULINUM TOXIN A; MANNOSE; PROBIOTIC AGENT; ANTIINFECTIVE AGENT; PLANT MEDICINAL PRODUCT;

ANTIBIOSIS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; AUTONOMIC DYSREFLEXIA; BLADDER DYSFUNCTION; BLADDER IRRIGATION; CRANBERRY JUICE; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; INFECTION PREVENTION; MORBIDITY; NEUROGENIC BLADDER; NONHUMAN; PATHOGENESIS; POSTVOID RESIDUAL URINE VOLUME; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SEPSIS; SPINAL CORD INJURY; URINARY CATHETER; URINARY TRACT INFECTION; URINE CULTURE; UROPATHOGENIC ESCHERICHIA COLI; ADVERSE EFFECTS; BLADDER; CATHETER-RELATED INFECTIONS; COMPLICATION; CRANBERRY; LAVAGE; PATHOPHYSIOLOGY; PHYTOTHERAPY; URETHRAL CATHETERIZATION; URINARY BLADDER, NEUROGENIC; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; CATHETER-RELATED INFECTIONS; HUMANS; INTERMITTENT URETHRAL CATHETERIZATION; MANNOSE; PHYTOTHERAPY; PLANT PREPARATIONS; PROBIOTICS; THERAPEUTIC IRRIGATION; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY TRACT INFECTIONS; VACCINIUM MACROCARPON;

EID: 84945444787     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2015.05.006     Document Type: Review

References (67)

1. Garcia Leoni M., Esclarin De Ruz A. Management of urinary tract infection in patients with spinal cord injuries. Clin Microbiol Infect 2003, 9(8):780-785.
2. Smith ED. Spina bifida and the total care of spinal myelomeningocele. Springfield (IL): 1965.
3. Burns A.S., Rivas D.A., Ditunno J.F. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine 2001, 26(24S):S129-S136.
4. Chaudhry R., Madden-Fuentes R.J., Ortiz T.K., et al. Inflammatory response to Escherichia coli urinary tract infection in the neurogenic bladder of the spinal cord injured host. J Urol 2014, 191(5):1454-1461.
5. Manack A., Motsko S.P., Haag-Molkenteller C., et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn 2011, 30(3):395-401.
6. Wang H.S., Tejwani R., Zhang H., et al. Hospital surgical volume and associated post-operative complications of pediatric urologic surgery in the United States. J Urol 2015, [Epub ahead of print].
7. Siroky M.B. Pathogenesis of bacteriuria and infection in the spinal cord injured patient. Am J Med 2002, 113(1):67-79.
8. Cameron A.P., Wallner L.P., Tate D.G., et al. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol 2010, 184(1):213-217.
9. Seki N., Masuda K., Kinukawa N., et al. Risk factors for febrile urinary tract infection in children with myelodysplasia treated by clean intermittent catheterization. Int J Urol 2004, 11(11):973-977.
10. Vasudeva P., Madersbacher H. Factors implicated in pathogenesis of urinary tract infections in neurogenic bladders: some revered, few forgotten, others ignored. Neurourol Urodyn 2014, 33(1):95-100.
11. Andriole V.T., Lytton B. The effect and critical duration of increased tissue pressure on susceptibility to bacterial infection. Br J Exp Pathol 1965, 46(3):308-317.
12. Mehrotra R. An experimental study of the vesical circulation during distension and in cystitis. J Pathol Bacteriol 1953, 66(1):79-89.
13. Kershen R.T., Azadzoi K.M., Siroky M.B. Blood flow, pressure and compliance in the male human bladder. J Urol 2002, 168(1):121-125.
14. Norden C.W., Green G.M., Kass E.H. Antibacterial mechanisms of the urinary bladder. J Clin Invest 1968, 47(12):2689-2700.
15. Merritt J.L. Residual urine volume: correlate of urinary tract infection in patients with spinal cord injury. Arch Phys Med Rehabil 1981, 62(11):558-561.
16. Dromerick A.W., Edwards D.F. Relation of postvoid residual to urinary tract infection during stroke rehabilitation. Arch Phys Med Rehabil 2003, 84(9):1369-1372.
17. Kim B., Lim J.H., Lee S.A., et al. The relation between postvoid residual and occurrence of urinary tract infection after stroke in rehabilitation unit. Ann Rehabil Med 2012, 36(2):248-253.
18. Balsara Z.R., Ross S.S., Dolber P.C., et al. Enhanced susceptibility to urinary tract infection in the spinal cord-injured host with neurogenic bladder. Infect Immun 2013, 81(8):3018-3026.
19. Schlager T.A., Dilks S., Trudell J., et al. Bacteriuria in children with neurogenic bladder treated with intermittent catheterization: natural history. J Pediatr 1995, 126(3):490-496.
20. Mitsui T., Minami K., Furuno T., et al. Is suprapubic cystostomy an optimal urinary management in high quadriplegics? A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol 2000, 38(4):434-438.
21. Chao R., Clowers D., Mayo M.E. Fate of upper urinary tracts in patients with indwelling catheters after spinal cord injury. Urology 1993, 42(3):259-262.
22. Cardenas D.D., Moore K.N., Dannels-McClure A., et al. Intermittent catheterization with a hydrophilic-coated catheter delays urinary tract infections in acute spinal cord injury: a prospective, randomized, multicenter trial. PM R 2011, 3(5):408-417.
23. Li L., Ye W., Ruan H., et al. Impact of hydrophilic catheters on urinary tract infections in people with spinal cord injury: systematic review and meta-analysis of randomized controlled trials. Arch Phys Med Rehabil 2013, 94(4):782-787.
24. Tenke P., Kovacs B., Johansen T.E., et al. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents 2008, 31:68-78.
25. Esclarín De Ruz A., García Leoni E., Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol 2000, 164(4):1285-1289.
26. Mulvey M.A., Schilling J.D., Hultgren S.J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 2001, 69(7):4572-4579.
27. Rosen D.A., Pinkner J.S., Jones J.M., et al. Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression. Infect Immun 2008, 76(7):3337-3345.
28. Berry R.E., Klumpp D.J., Schaeffer A.J. Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli. Infect Immun 2009, 77(7):2762-2772.
29. Blango M.G., Mulvey M.A. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 2010, 54(5):1855-1863.
30. Mahadeva A., Tanasescu R., Gran B. Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large university hospital. Am J Clin Exp Immunol 2014, 3(1):57.
31. Cameron A.P., Rodriguez G.M., Schomer K.G. Systematic review of urological followup after spinal cord injury. J Urol 2012, 187(2):391-397.
32. Madden-Fuentes R.J., Ross S.S. Urinary tract infections in the spina bifida population. Novel Insights into Urinary Tract Infections and Their Management 2014, 61.
33. The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation research consensus statement. January 27-29, 1992. J Am Paraplegia Soc 1992, 15(3):194-204.
34. Jahromi M.S., Mure A., Gomez C.S. UTIs in patients with neurogenic bladder. Curr Urol Rep 2014, 15(9):1-7.
35. Wyndaele J., Brauner A., Geerlings S.E., et al. Clean intermittent catheterization and urinary tract infection: review and guide for future research. BJU Int 2012, 110(11c):E910-E917.
36. Massa L.M., Hoffman J.M., Cardenas D.D. Validity, accuracy, and predictive value of urinary tract infection signs and symptoms in individuals with spinal cord injury on intermittent catheterization. J Spinal Cord Med 2009, 32(5):568-573.
37. Linsenmeyer T.A., Oakley A. Accuracy of individuals with spinal cord injury at predicting urinary tract infections based on their symptoms. J Spinal Cord Med 2003, 26(4):352-357.
38. Hooton T.M., Bradley S.F., Cardenas D.D., et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010, 50(5):625-663.
39. Nicolle L.E. Consequences of asymptomatic bacteriuria in the elderly. Int J Antimicrob Agents 1994, 4(2):107-111.
40. Hooton T.M. Uncomplicated urinary tract infection. N Engl J Med 2012, 366(11):1028-1037.
41. Yoon S., Lee B., Lee K., et al. Comparison of bacterial strains and antibiotic susceptibilities in urinary isolates of spinal cord injury patients from the community and hospital. Spinal Cord 2014, 52(4):298-301.
42. Nicolle L.E. Urinary tract infections in patients with spinal injuries. Curr Infect Dis Rep 2014, 16(1):1-7.
43. Schlager T.A., Anderson S., Trudell J., et al. Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. J Pediatr 1998, 132(4):704-708.
44. Morton S.C., Shekelle P.G., Adams J.L., et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil 2002, 83(1):129-138.
45. Zegers B., Uiterwaal C., Kimpen J., et al. Antibiotic prophylaxis for urinary tract infections in children with spina bifida on intermittent catheterization. J Urol 2011, 186(6):2365-2371.
46. Mohler J.L., Cowen D.L., Flanigan R.C. Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder. J Urol 1987, 138(2):336-340.
47. Craig J.C., Williams G.J., Hodson E.M. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med 2014, 371(11):1070-1073.
48. Dow G., Rao P., Harding G., et al. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clin Infect Dis 2004, 39(5):658-664.
49. Darouiche R.O., Al Mohajer M., Siddiq D.M., et al. Short versus long course of antibiotics for catheter-associated urinary tract infections in patients with spinal cord injury: a randomized controlled noninferiority trial. Arch Phys Med Rehabil 2014, 95(2):290-296.
50. Everaert K., Lumen N., Kerckhaert W., et al. Urinary tract infections in spinal cord injury: prevention and treatment guidelines. Acta Clin Belg 2009, 64(4):335-340.
51. Jepson R.G., Craig J.C. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2008, (1). CD001321.
52. Kranjčec B., Papeš D., Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol 2014, 32(1):79-84.
53. Hull R., Rudy D., Donovan W., et al. Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord injured patients. J Urol 2000, 163(3):872-877.
54. Darouiche R.O., Green B.G., Donovan W.H., et al. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology 2011, 78(2):341-346.
55. Rudick C.N., Taylor A.K., Yaggie R.E., et al. Asymptomatic bacteriuria Escherichia coli are live biotherapeutics for UTI. PLoS One 2014, 9(11):e109321.
56. Lutay N., Ambite I., Gronberg Hernandez J., et al. Bacterial control of host gene expression through RNA polymerase II. J Clin Invest 2013, 123(6):2366-2379.
57. Bao Y., Welk B., Reid G., et al. Role of the microbiome in recurrent urinary tract infection. Novel Insights into Urinary Tract Infections and Their Management 2014, 49.
58. Prasad A., Cevallos M.E., Riosa S., et al. A bacterial interference strategy for prevention of UTI in persons practicing intermittent catheterization. Spinal Cord 2009, 47(7):565-569.
59. Stapleton A.E., Au-Yeung M., Hooton T.M., et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 2011, 52(10):1212-1217.
60. ter Riet G., Nys S., van der Wal W.M., et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012, 172(9):704-712.
61. Elliott T., Reid L., Rao G.G., et al. Bladder irrigation or irritation?. Br J Urol 1989, 64(4):391-394.
62. Damiano R., Quarto G., Bava I., et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol 2011, 59(4):645-651.
63. Mañas A., Glaría L., Peña C., et al. Prevention of urinary tract infections in palliative radiation for vertebral metastasis and spinal compression: a pilot study in 71 patients. Int J Radiat Oncol Biol Phys 2006, 64(3):935-940.
64. Jia C., Liao L., Chen G., et al. Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury. Spinal Cord 2013, 51(6):487-490.
65. Mouttalib S., Khan S., Castel-Lacanal E., et al. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int 2010, 106(11):1677-1680.
66. Salomon J., Denys P., Merle C., et al. Prevention of urinary tract infection in spinal cord-injured patients: safety and efficacy of a weekly oral cyclic antibiotic (WOCA) programme with a 2 year follow-up-an observational prospective study. J Antimicrob Chemother 2006, 57(4):784-788.
67. Johnson J.R., Johnston B., Clabots C., et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010, 51(3):286-294.